R3655
Rubitecan
powder, ≥98% (HPLC)
别名:
9-nitrocamptothecin
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H15N3O6
化学文摘社编号:
分子量:
393.35
MDL编号:
UNSPSC代码:
12352204
PubChem化学物质编号:
NACRES:
NA.77
产品名称
Rubitecan,
生物来源
synthetic (organic)
质量水平
方案
≥98% (HPLC)
表单
powder
mp
182-186 °C
溶解性
DMSO: 1 mg/mL
储存温度
room temp
SMILES字符串
CC[C@@]1(O)C(=O)OCC2=C1C=C3N(Cc4cc5c(cccc5nc34)[N+]([O-])=O)C2=O
InChI
1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1
InChI key
VHXNKPBCCMUMSW-FQEVSTJZSA-N
生化/生理作用
Topoisomerase I inhibitor. Rubitecan induces protein- linked DNA single strand breaks, blocking DNA and RNA synthesis in dividing cells. This mode of action makes rubitecan a potential chemotherapeutic agent, and it has been used with some success against refractory pancreatic cancer.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Shunzhen Zheng et al.
PloS one, 6(6), e21064-e21064 (2011-06-23)
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related mortality worldwide. 9-Nitrocamptothecin (9NC) is a potent topoisomerase-I inhibitor with strong anticancer effect. To increase the solubility and stability, we synthesized a novel 9NC loaded liposomes (9NC-LP) via
Alfonso Quintas-Cardama et al.
Cancer, 107(7), 1525-1529 (2006-09-07)
Topoisomerase I inhibitors, like topotecan, have activity in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). 9-Nitro-camptothecin (9-NC) is a new oral topoisomerase inhibitor with a good safety profile. The aims of the current study were to evaluate the activity
Complex of 9-nitro-camptothecin in hydroxypropyl-beta-cyclodextrin: in vitro and in vivo evaluation.
Ye Jiang et al.
International journal of pharmaceutics, 397(1-2), 116-121 (2010-07-20)
The effect of a series of cyclodextrins (CDs), especially hydroxypropyl-beta-cyclodextrin (HP-beta-CD), on aqueous solubility and chemical stability of 9-nitro-camptothecin (9-NC), was investigated with an aim of preparing a stable and effective parenteral formulation. The 9-NC/HP-beta-CD complex was obtained in solid
Li-Jun Zhang et al.
Pulmonary pharmacology & therapeutics, 21(1), 239-246 (2007-06-15)
This study was designed to investigate in vitro release, in vivo tissue distribution and the damage to the lungs of 9-nitrocamptothecin (9-NC) liposomes. In vitro release of 9-NC from liposomes was carried out in phosphate buffer saline solution (PBS) pH
Juan-Li Lu et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 69(3), 899-907 (2008-04-25)
9-Nitrocamptothecin (9-NC) is an orally administered topoisomerase-I inhibitor for the treatment of pancreatic carcinoma, but its oral absorption and bioavailability are poor. The main objective of this study was to develop optimal 9-nitrocamptothecin (9-NC) microemulsion prepared by self-microemulsifying drug delivery
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持